Ifosfamide in small cell lung cancer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ifosfamide, an analogue of cyclophosphamide, has been proven to be of value in numerous malignancies, including testicular cancer, sarcoma, and lymphoma. Furthermore, ifosfamide is more suitable for combination chemotherapy than its parent compound because it causes less myelosuppression than cyclophosphamide. There have been only a few studies evaluating single-agent ifosfamide in small cell lung cancer (SCLC). In patients who have had little or no prior chemotherapy, ifosfamide appears as active as any single agent. Combination chemotherapy regimens employing cisplatin (or carboplatin) plus etoposide plus ifosfamide are currently under way on both sides of the Atlantic. A Hoosier Oncology Group (HOG) study will evaluate this three-drug regimen v cisplatin plus etoposide, and this protocol will establish or refute the value of ifosfamide as first-line therapy in extensive SCLC.

Original languageEnglish
Pages (from-to)19-21
Number of pages3
JournalSeminars in Oncology
Volume16
Issue number1 SUPPL. 3
StatePublished - 1989

Fingerprint

Ifosfamide
Small Cell Lung Carcinoma
Etoposide
Combination Drug Therapy
Cyclophosphamide
Cisplatin
Carboplatin
Testicular Neoplasms
Sarcoma
Lymphoma
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Ifosfamide in small cell lung cancer. / Einhorn, Lawrence.

In: Seminars in Oncology, Vol. 16, No. 1 SUPPL. 3, 1989, p. 19-21.

Research output: Contribution to journalArticle

Einhorn, L 1989, 'Ifosfamide in small cell lung cancer', Seminars in Oncology, vol. 16, no. 1 SUPPL. 3, pp. 19-21.
Einhorn, Lawrence. / Ifosfamide in small cell lung cancer. In: Seminars in Oncology. 1989 ; Vol. 16, No. 1 SUPPL. 3. pp. 19-21.
@article{4bf0b12c14d54b38a37209a60126e771,
title = "Ifosfamide in small cell lung cancer",
abstract = "Ifosfamide, an analogue of cyclophosphamide, has been proven to be of value in numerous malignancies, including testicular cancer, sarcoma, and lymphoma. Furthermore, ifosfamide is more suitable for combination chemotherapy than its parent compound because it causes less myelosuppression than cyclophosphamide. There have been only a few studies evaluating single-agent ifosfamide in small cell lung cancer (SCLC). In patients who have had little or no prior chemotherapy, ifosfamide appears as active as any single agent. Combination chemotherapy regimens employing cisplatin (or carboplatin) plus etoposide plus ifosfamide are currently under way on both sides of the Atlantic. A Hoosier Oncology Group (HOG) study will evaluate this three-drug regimen v cisplatin plus etoposide, and this protocol will establish or refute the value of ifosfamide as first-line therapy in extensive SCLC.",
author = "Lawrence Einhorn",
year = "1989",
language = "English",
volume = "16",
pages = "19--21",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 3",

}

TY - JOUR

T1 - Ifosfamide in small cell lung cancer

AU - Einhorn, Lawrence

PY - 1989

Y1 - 1989

N2 - Ifosfamide, an analogue of cyclophosphamide, has been proven to be of value in numerous malignancies, including testicular cancer, sarcoma, and lymphoma. Furthermore, ifosfamide is more suitable for combination chemotherapy than its parent compound because it causes less myelosuppression than cyclophosphamide. There have been only a few studies evaluating single-agent ifosfamide in small cell lung cancer (SCLC). In patients who have had little or no prior chemotherapy, ifosfamide appears as active as any single agent. Combination chemotherapy regimens employing cisplatin (or carboplatin) plus etoposide plus ifosfamide are currently under way on both sides of the Atlantic. A Hoosier Oncology Group (HOG) study will evaluate this three-drug regimen v cisplatin plus etoposide, and this protocol will establish or refute the value of ifosfamide as first-line therapy in extensive SCLC.

AB - Ifosfamide, an analogue of cyclophosphamide, has been proven to be of value in numerous malignancies, including testicular cancer, sarcoma, and lymphoma. Furthermore, ifosfamide is more suitable for combination chemotherapy than its parent compound because it causes less myelosuppression than cyclophosphamide. There have been only a few studies evaluating single-agent ifosfamide in small cell lung cancer (SCLC). In patients who have had little or no prior chemotherapy, ifosfamide appears as active as any single agent. Combination chemotherapy regimens employing cisplatin (or carboplatin) plus etoposide plus ifosfamide are currently under way on both sides of the Atlantic. A Hoosier Oncology Group (HOG) study will evaluate this three-drug regimen v cisplatin plus etoposide, and this protocol will establish or refute the value of ifosfamide as first-line therapy in extensive SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0024565255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024565255&partnerID=8YFLogxK

M3 - Article

C2 - 2539644

AN - SCOPUS:0024565255

VL - 16

SP - 19

EP - 21

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 3

ER -